☆ 4.7 Review

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Biology

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer

Noriko Kishi et al.

Summary: Chemoradiotherapy followed by consolidation durvalumab improves survival in patients with stage III non-small-cell lung cancer (NSCLC). The study compared recurrence patterns and survival rates between different treatment groups and found that consolidation durvalumab reduced locoregional recurrence and distant metastasis, leading to improved progression-free survival.

JOURNAL OF RADIATION RESEARCH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer

Vetriselvan Subramaniyan et al.

Summary: EGFR is a crucial cell receptor that plays a significant role in tumor development and treatment, impacting various cancers such as glioblastoma and breast cancer. Therapies involving anti-Herceptin and other targeted drugs have shown promise in improving patient prognosis.

CHEMICO-BIOLOGICAL INTERACTIONS (2022)

Add to Collection

Article Oncology

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

David R. Spigel et al.

Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial

Cecile Le Pechoux et al.

Summary: This study aimed to investigate whether three-dimensional conformal radiotherapy (3D PORT) should be part of the standard treatment for patients with non-small-cell lung cancer (NSCLC) with N2 involvement. The results showed that 3-year disease-free survival was slightly higher in patients with PORT compared to those without, but the difference was not significant.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study

Rodolfo Chicas-Sett et al.

Summary: Combining anti-PD-1 and SABR in oligoprogressive metastatic NSCLC or melanoma can achieve high rates of tumor response and extend the clinical benefit of immunotherapy by delaying further progression and the need for new systemic therapy. This approach should be evaluated in larger randomized trials.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan et al.

Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

Paolo Borghetti et al.

Summary: This article describes the pattern of relapse, progression-free survival (PFS), and overall survival (OS) in patients treated with radio-chemotherapy and durvalumab for loco-regional relapse after surgical resection of non-small-cell lung cancer (NSCLC). The results suggest that this treatment strategy may prolong post recurrence survival in patients with good performance status experiencing loco-regional relapse after surgery.

RADIATION ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT)

M. J. Mooradian et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer

Shivkanya Fuloria et al.

Summary: Evidence suggests that reactive oxygen species (ROS) play complex roles in cancer, with both beneficial and harmful effects, depending on concentration. Further research is needed to understand the relationship between ROS, antioxidants, and cancer, and to develop more accurate methods for ROS detection.

ANTIOXIDANTS (2021)

Add to Collection

Article Oncology

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

Julian Taugner et al.

Summary: This prospective study evaluated the clinical use and real-world efficacy of Durvalumab maintenance treatment after chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer patients. The results showed a favorable safety profile of Durvalumab maintenance treatment, with 27% of patients discontinuing treatment due to disease progression, all of whom were eligible for second-line treatment.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Alessio Bruni et al.

Summary: This study reports on the safety and efficacy of durvalumab maintenance therapy in unresectable stage III NSCLC patients after CRT in a real-world, multicenter, retrospective cohort. The results showed promising short-term survival outcomes, with no significant differences in progression-free survival or overall survival between concurrent and sequential CRT. Notably, immune-related adverse events were observed in almost half of the patients, with pneumonitis being the most common cause of treatment discontinuation.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

S. Patel et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Oncology

Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO

Silvia Scoccianti et al.

Summary: In a multicentric retrospective study from AIRO, the combination of stereotactic radiotherapy (SRT) and immunotherapy (IT) showed better intracranial local progression-free survival in non-small cell lung cancer (NSCLC) patients with brain metastases. Additionally, treating NSCLC patients with IT after extracranial progression at the time of brain metastases diagnosis was associated with improved overall survival.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Respiratory System

Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post-operative recurrent pulmonary pleomorphic carcinoma

So Shimamura et al.

Summary: This case suggests that multidisciplinary treatment with chemoradiotherapy and consolidation immunotherapy may improve the prognosis of locally advanced PPC.

RESPIROLOGY CASE REPORTS (2021)

Add to Collection

Review Oncology

Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC

Eric D. Brooks et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection-can local recurrence be radically cured by radiation?

Yukihiro Terada et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer

Eric D. Brooks et al.

JAMA NETWORK OPEN (2018)

Add to Collection

© Peeref 2019-2024. All rights reserved.